Cargando…
Lung metastases from melanoma: when is surgical treatment warranted?
Surgical treatment of lung metastases from melanoma is highly controversial as the expected outcome is much poorer than for other primary tumours and a reliable system for selecting patients is lacking. This study evaluated the long-term results of lung metastasectomy for melanoma, with the aim of d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363508/ https://www.ncbi.nlm.nih.gov/pubmed/10944593 http://dx.doi.org/10.1054/bjoc.2000.1335 |
_version_ | 1782153722303873024 |
---|---|
author | Leo, F Cagini, L Rocmans, P Cappello, M Geel, A N Van Maggi, G Goldstraw, P Pastorino, U |
author_facet | Leo, F Cagini, L Rocmans, P Cappello, M Geel, A N Van Maggi, G Goldstraw, P Pastorino, U |
author_sort | Leo, F |
collection | PubMed |
description | Surgical treatment of lung metastases from melanoma is highly controversial as the expected outcome is much poorer than for other primary tumours and a reliable system for selecting patients is lacking. This study evaluated the long-term results of lung metastasectomy for melanoma, with the aim of defining a subset of patients with better prognosis. By reviewing the data of the International Registry of Lung Metastases (IRLM), we identified 328 patients who underwent lung metastasectomy for melanoma in the period 1945–1995. Survival was calculated by Kaplan–Meier estimate, using log-rank test and Cox regression model for statistical analysis. After complete pulmonary metastasectomy (282 patients) the 5- and 10-year survival was 22% and 16%, respectively. In this group of patients, a time to pulmonary metastases (TPM) shorter than 36 months or the presence of multiple metastases were independent unfavourable prognostic factors. There were no long-term survivors after incomplete resection (46 patients, P< 0.01). Using the IRLM grouping system, patients without risk factors (TPM > 36 months and single lesion) experienced the best survival (29% at 5 years), followed by those with one risk factor only (20% at 5 years). On the other hand, those with two risk factors or incomplete resection showed a significantly poorer survival (7% and 0% at 5 years). Surgery plays an important role in carefully selected cases of pulmonary metastatic melanoma. The prognostic grouping system proposed by the International Registry of Lung Metastases provides a simple and effective method for improving the selection of surgical candidates. © 2000 Cancer Research Campaign |
format | Text |
id | pubmed-2363508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23635082009-09-10 Lung metastases from melanoma: when is surgical treatment warranted? Leo, F Cagini, L Rocmans, P Cappello, M Geel, A N Van Maggi, G Goldstraw, P Pastorino, U Br J Cancer Regular Article Surgical treatment of lung metastases from melanoma is highly controversial as the expected outcome is much poorer than for other primary tumours and a reliable system for selecting patients is lacking. This study evaluated the long-term results of lung metastasectomy for melanoma, with the aim of defining a subset of patients with better prognosis. By reviewing the data of the International Registry of Lung Metastases (IRLM), we identified 328 patients who underwent lung metastasectomy for melanoma in the period 1945–1995. Survival was calculated by Kaplan–Meier estimate, using log-rank test and Cox regression model for statistical analysis. After complete pulmonary metastasectomy (282 patients) the 5- and 10-year survival was 22% and 16%, respectively. In this group of patients, a time to pulmonary metastases (TPM) shorter than 36 months or the presence of multiple metastases were independent unfavourable prognostic factors. There were no long-term survivors after incomplete resection (46 patients, P< 0.01). Using the IRLM grouping system, patients without risk factors (TPM > 36 months and single lesion) experienced the best survival (29% at 5 years), followed by those with one risk factor only (20% at 5 years). On the other hand, those with two risk factors or incomplete resection showed a significantly poorer survival (7% and 0% at 5 years). Surgery plays an important role in carefully selected cases of pulmonary metastatic melanoma. The prognostic grouping system proposed by the International Registry of Lung Metastases provides a simple and effective method for improving the selection of surgical candidates. © 2000 Cancer Research Campaign Nature Publishing Group 2000-09 2000-08-16 /pmc/articles/PMC2363508/ /pubmed/10944593 http://dx.doi.org/10.1054/bjoc.2000.1335 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Leo, F Cagini, L Rocmans, P Cappello, M Geel, A N Van Maggi, G Goldstraw, P Pastorino, U Lung metastases from melanoma: when is surgical treatment warranted? |
title | Lung metastases from melanoma: when is surgical treatment warranted? |
title_full | Lung metastases from melanoma: when is surgical treatment warranted? |
title_fullStr | Lung metastases from melanoma: when is surgical treatment warranted? |
title_full_unstemmed | Lung metastases from melanoma: when is surgical treatment warranted? |
title_short | Lung metastases from melanoma: when is surgical treatment warranted? |
title_sort | lung metastases from melanoma: when is surgical treatment warranted? |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363508/ https://www.ncbi.nlm.nih.gov/pubmed/10944593 http://dx.doi.org/10.1054/bjoc.2000.1335 |
work_keys_str_mv | AT leof lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted AT caginil lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted AT rocmansp lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted AT cappellom lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted AT geelanvan lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted AT maggig lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted AT goldstrawp lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted AT pastorinou lungmetastasesfrommelanomawhenissurgicaltreatmentwarranted |